|Bid||8.32 x 0|
|Ask||8.34 x 0|
|Day's range||8.23 - 8.44|
|52-week range||7.45 - 11.59|
|Beta (5Y monthly)||0.02|
|PE ratio (TTM)||16.23|
|Forward dividend & yield||0.27 (3.16%)|
|Ex-dividend date||20 Aug 2020|
|1y target est||19.00|
Glanbia (ISE:GL9) has had a rough three months with its share price down 8.7%. But if you pay close attention, you...
Irish nutrition group Glanbia outlined steps to simplify and improve the performance of its division that sells products aimed at athletes and body builders as full year earnings fell in line with company guidance. Glanbia cut its earnings guidance for 2019 in July after performance nutrition sales volumes were weaker than expected because it faced currency and tariff headwinds in major non-U.S. markets, including Brazil, the Middle East and India. Measures to improve the Glanbia Performance Nutrition (GPN) included exiting low margin areas including the majority of U.S. contract manufacture business, managing the division as four distinct businesses and optimising routes to market.
Shares in nutrition group Glanbia fell by more than 10% on Thursday after it reported continued weakness in sales of products aimed at athletes and body builders. The Irish company said sales volumes in its performance nutrition business were weaker than expected because it faced currency and tariff headwinds in major non-US markets, including Brazil, Middle East and India. A shift to online sales in Europe also had an impact.